Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat

Headache

Volumn 46, Issue 2, 2006, Pages 276-285

  Schuh Hofer, Sigrid ^a,b   Tayefeh, Mandana ^a,b   Reuter, Uwe ^a,b   Dirnagl, Ulrich ^a,b   Arnold, Guy ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Clinical and Experimental Neurology ^*  (Germany)

Author keywords

c fos expression; Cyclooxygenase 2; Migraine; Neurogenic inflammation; Parecoxib

Indexed keywords

PARECOXIB; PLASMA PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN C FOS; SUMATRIPTAN SUCCINATE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DURA MATER; ELECTROSTIMULATION; MALE; MENINX; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RAT STRAIN; TRIGEMINAL NUCLEUS; TRIGEMINUS GANGLION;

ANIMALS; BLOOD PROTEINS; CAPILLARY PERMEABILITY; CYCLOOXYGENASE 2 INHIBITORS; DURA MATER; ISOXAZOLES; MALE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33645072998     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00332.x     Document Type: Article

References (49)

1. Buzzi MG Moskowitz MA Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine Cephalalgia 1991 11 165 168
2. Williamson DJ Shepheard SL Hill RG Hargreaves RL The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation Eur J Pharmacol 1997 328 61 64
3. Martin GR Pre-clinical pharmacology of zolmitriptan (Zomig, formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine Cephalalgia 1997 17 suppl 18 4 14
4. Gras J Bou J Llenas J Fernandez AG Palacios JM Functional profile of almotriptan in animal models predictive of antimigraine activity Eur J Pharmacol 2000 410 43 51
5. Limmroth V Katsarava Z Diener HC Acetylsalicylic acid in the treatment of headache Cephalalgia 1999 19 546 551
6. Silberstein S Tepper S Brandes J et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine Neurology 2004 62 1552 1557
7. Goebel H Heinze A Heinze-Kuhn K Parecoxib i.v. in der Behandlung der akuten Migräneattacke als Ersatzmedikation bei Ineffektivität von Triptanen Aktuelle Neurologie 2003 Suppl S1 776
8. Mukherjee D Nissen SE Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 2001 286 95495 9
9. Ray WA Stein CM Daugherty JR Hall K Arbogast PG Griffin MR COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 2002 360 1071 1073
10. Juni P Nartey L Reichenbach S Sterchi R Dieppe PA Egger M Risk of cardiovascular events and rofecoxib: cumulative meta-analysis Lancet 2004 364 2021 2029
11. Garavito RM DeWitt DL The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins Biochem Biophys Acta 1999 1441 278 287
12. Buzzi MG Sakas DE Moskowitz MA Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater Eur J Pharmacol 1989 165 251 258
13. Stichtenoth DO Frölich JC The second generation of COX-2 inhibitors. What advantages do the newest offer¿ Drugs 2003 63 33 45
14. Markowitz S Saito K Moskowitz MA Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain J Neurosci 1987 7 4129 4136
15. Clayton JS Gaskin PJ Beattie DT Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig Brain Res 1997 775 74 80
16. Mitsikostas DD Sanchez del Rio M Moskowitz MA Waeber C Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis Eur J of Pharmacol 1999 369 271 277
17. Mitsikostas DD Sanchez del Rio M Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine Brain Res Rev 2001 35 20 35
18. Schuh-Hofer S Boehnke C Reuter U et al. A fluorescence-based method to assess plasma protein extravasation in rat dura mater using confocal laser scanning microscopy Brain Res Protoc 2003 12 77 82
19. Padi SSV Jain NK Sigh S Kulkarni SK Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor Eur J Pharmacol 2004 491 69 76
20. Shepard SL Williamson DJ Williams J Hill RG Hargreaves RJ Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats Neuropharmacology 1995 34 255 261
21. Baba H Kohno T Moore KA Woolf CJ Direct activation of rat spinal dorsal horn neurons by prostaglandin E2 J Neurosci 2001 2 1750 1756
22. Ma W Eisenach JC Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain Eur J Neurosci 2002 15 1037 1047
23. Samad TA Moore KA Sapirstein A et al. Interleukin-1beta mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity Nature 2001 410 471 475
24. Samad TA Sapirstein A Woolf CJ Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets Trends Mol Med 2002 8 390 396
25. Vane JR Mitchell JA Appleton I et al. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation Proc Natl Acad Sci U S A 1994 91 2046 2050
26. Vane JR Bakhle YS Botting RM Cyclooxygenase 1 and 2 Annu Rev Pharmacol Toxicol 1998 38 97 120
27. Ibuki T Matsumura K Yamazaki Y Nozaki T Tanaka Y Kobayashi S Cycloogenase-2 is induced in the endothelial cells throughout the central nervous system during carrageenan-induced hind paw inflammation; its possible role in hyperalgesia J Neurochem 2003 86 318 328
28. Beiche F Scheuerer S Brune K Geisslinger G Goppelt-Struebe M Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation FEBS Lett 1996 390 165 169
29. Anderson GD Hauser SD McGarity KL Bremer ME Isakson PC Gregory SA Selective inhibition of cyclyoxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis J Clin Invest 1996 97 2672 2679
30. Seibert K Zhang Y Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain Proc Natl Acad Sci U S A 1994 91 12013 12017
31. Edvinsson L Goadsby PJ Neuropeptides in migraine and cluster headache Cephalalgia 1994 14 320 327
32. Limmroth V Cutrer FM Moskowitz MA Neurotransmitters and neuropeptides in headache Curr Opin Neurol 1996 9 206 210
33. Limmroth V Katsarava Z Liedert B et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system Pain 2001 92 101 106
34. Ebersberger A Averbeck B Messlinger K Reeh PW Release of substance P, calcitionin-gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro Neuroscience 1999 89 901 907
35. Jenkins DV Jarvie E Feniuk W Humphrey PPA Bradykinin-induced prostaglandin E2 and CGRP release from rat trigeminal ganglion neurones in vitro Cephalalgia 2001 21 355
36. Jenkins DW Sellers LA Feniuk W Humphrey PPA Characterization of bradykinin-induced prostaglandin E2 release from cultured rat trigeminal ganglion neurones Eur J Pharmacol 2003 469 29 36
37. Tuca JO Planas JM Parellada PP Increase in PGE2 and TXA2 in the saliva of common migraine patiens. Action of calcium channel blockers Headache 1989 29 498 501
38. Sarchielli P Alberti A Codini M Florida A Gallai V Nitric oxice metabolites, prostaglandins and trigeminal vasoacative peptides in internal jugular vein blood during spontaneous migraine attacks Cephalalgia 2000 20 907 918
39. Durham P Russo A New insights into the molecular actions of serotonergic antimigraine drugs Pharmacol Ther 2002 94 77 92
40. Goadsby PJ Edvinsson L The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seeen in humans and cats Ann Neurol 1993 28 183 187
41. Buzzi MG Carter WB Shimizu T Heath H Moskowitz MA Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion Neuropharmacology 1991b 30 1193 1200
42. Tannenbaum H Davis P Russell AS et al. An evidence-based approach to prescribing NSAIDs in muskuloskeletal disease: a Canadian consensus Can Med Assoc J 1996 155 77 88
43. Vasko MR Campbell WB Waite KJ Prostaglanin E2 enhances bradykinin-stimulated release of neuropeptides from rat sensory neurons in culture J Neurosci 1994 14 4987 4997
44. Hingtgen CM Waite KJ Vasko MR Prostaglandins facilitate peptide release from rat sensory neurons by activating the Adenosine 3′,5′-Cyclic Monophosphate transduction cascade J Neurosci 1995 15 5411 5419
45. Nicol GD Klingberg DK Vasko MR Prostaglandins E2 increases calcium conductance and stimulates release of Substance P in avian sensory neurons J Neurosci 1992 12 1917 1927
46. Jenkins DW Feniuk W Humphrey PPA Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones Br J Pharmacol 2001 134 1296 1302
47. Zhang Y Shaffer A Portanova J Seibert K Isakson P Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production J Pharmacol Exp Ther 1997 283 1069 1075
48. Lacroix S Vallieres L Rivest S C-fos mRNA pattern and corticotropin-releasing factor neuronal activity throughout the brain of rats injected centrally with a prostaglandin of E2 type J Neuroimmunol 1996 70 163 179
49. Smith CJ Zhang Y Koboldt CM et al. Pharmacological analysis of cyclooxygenase-1 in inflammation Proc Natl Acad Sci U S A 1998 95 13313 13318